title: Neuropathy under chemotherapy.
abstract: Neuropathy is a dose-limiting side effect for a number of effective chemotherapeutic agents. A better understanding of effective mechanisms will lead to novel treatment strategies that will protect neurons without decreasing therapeutic efficacy. The assessment of the efficacy and neurotoxicity of various chemotherapeutic agents is vital, for a determination of the maximum allowable dose. The introduction of chemotherapy in the 50s and 60s of the twentieth century has resulted in the development of curative therapeutic interventions for patients with several types of solid tumours and hemopoietic neoplasms. The important obstacles encountered in the use of chemotherapy have been the toxicity to the normal tissue. During the past 8 years there has come about a new level of understanding of the mechanisms through which chemotherapeutic agents work. This has opened the door to new paradigms of treatment in which molecular, genetic, and biologic therapy can be used together to increase the sensitivity of abnormal cells to treatment, and to protect the normal tissues of the body from therapy-induced side effects. The implementation of new strategies could change the way therapy is delivered over the next few years and improve the outcome especially in patients with neoplasms that are currently resistant to conventional dose therapy.
authors.affiliation: Charité, Campus Mitte, Medizinische Klinik m.S. Onkologie und Hämatologie, Schumannstr. 20/21, D-10117 Berlin, Germany. thomas.beinert@charite.de
authors.forename: T
authors.initials: T
authors.lastname: Beinert
authors.forename: F
authors.initials: F
authors.lastname: Masuhr
authors.forename: E
authors.initials: E
authors.lastname: Mwela
authors.forename: M
authors.initials: M
authors.lastname: Schweigert
authors.forename: B
authors.initials: B
authors.lastname: Flath
authors.forename: H
authors.initials: H
authors.lastname: Harder
authors.forename: D
authors.initials: D
authors.lastname: Binder
authors.forename: C
authors.initials: C
authors.lastname: Oehm
authors.forename: F
authors.initials: F
authors.lastname: Behse
authors.forename: K
authors.initials: K
authors.lastname: Possinger
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009422:Nervous System Diseases / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents